Brookfield Corp’s Viridian Therapeutics VRDN Stock Holding History

Brookfield Corp’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27,915	Closed	-$815K	–	785
2022 Q4	$815K	Buy	+27,915	New	+$643K	﹤0.01%	519

Other funds holding VRDN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Brookfield Corp's VRDN Position: Q1 2023 in Review

Brookfield Corp sold out of Viridian Therapeutics (VRDN) in Q1 2023, closing a stake of 27,915 shares — an estimated $815K sold.

Brookfield Corp first reported a position in VRDN in Q4 2022 and held it in 1 quarter. The position peaked at $815K in Q4 2022. 135 funds tracked by Wall St. Rank hold VRDN as of Q1 2023.

Brookfield Corp reported no remaining Viridian Therapeutics position as of Q1 2023 after selling out during the quarter.
Brookfield Corp sold 27,915 Viridian Therapeutics shares in Q1 2023, an estimated $815K.
Brookfield Corp first reported a position in Viridian Therapeutics in Q4 2022 and held it in 1 quarter.
Brookfield Corp's Viridian Therapeutics position peaked at $815K in Q4 2022.
135 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.